Lindsie Goss, PhD is a Senior Technology Manager in the Business Development and Strategy (BD&S) office at Fred Hutchinson Cancer Research Center in Seattle, WA. Lindsie’s primary role is to create and partner with companies in the cell and gene therapy space, with a focus on immuno-oncology and adoptive T cell therapies. Lindsie manages an IP portfolio of about 120 inventions covered by approximately 450 patent applications and patents. Since 2016, this portfolio has led to the execution of 8 exclusive licenses/options valuing over $64M in potential deal revenue, excluding royalties and sublicensing consideration. Many of these IP transactions involve further development of the asset at Fred Hutch under industry sponsored preclinical and clinical research agreements. To date, Lindsie has brought in over $29M in preclinical sponsored research support to Fred Hutch.
Lindsie received Bachelor of Arts degrees from the University of California, Berkeley in Molecular and Cellular Biology- Genetics and Scandinavian Studies in 2006. After her undergraduate training, Lindsie joined the Microbiology and Immunology Department in the Graduate School of Arts and Sciences at Columbia University where she earned a Master of Arts in 2009, Master of Philosophy in 2012, and a Doctorate in Philosophy in 2013. Prior to joining Fred Hutch, Lindsie worked at the University of Washington CoMotion, the technology transfer office for the University of Washington, and as the Director of the Allied Minds Fellows Program for Allied Minds plc, an IP commercialization company focused on technology and life sciences based in Boston.